Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C)

C. Philip Steuber, Vita J. Land, Curt I. Civin, Abdel H. Ragab, Jeffrey Krischer, Teresa J. Vietti

Research output: Contribution to journalArticle

Abstract

To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C). Nineteen of 20 children with leukemia who received these agents developed fever requiring hospitalization. There were 4 deaths 2 due to proven infection. One patient developed nonfatal cardiotoxicity. No other significant toxicity was noted. Responses were seen in 7 of 20 patients. The recommended DHAD dosage was 8 mg/m2/day when given in combination with Ara-C.

Original languageEnglish (US)
Pages (from-to)379-382
Number of pages4
JournalInvestigational New Drugs
Volume5
Issue number4
DOIs
Publication statusPublished - Dec 1987

    Fingerprint

Keywords

  • DHAD/AraC combination

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Steuber, C. P., Land, V. J., Civin, C. I., Ragab, A. H., Krischer, J., & Vietti, T. J. (1987). Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). Investigational New Drugs, 5(4), 379-382. https://doi.org/10.1007/BF00169979